

Cirrhosis and Complication: Treatment and Prognosis

Guest Editor:

Prof. Dr. Irene Cacciola

Department of Clinical and
Experimental Medicine,
University of Messina and
University Hospital of Messina,
98125 Messina, Italy

Deadline for manuscript
submissions:

closed (20 May 2023)

Message from the Guest Editor


Cirrhosis represents the end stage of chronic liver disease because of different causes, including viral hepatitis, autoimmune and genetic illnesses, alcohol abuse and metabolic disorders. The term cirrhosis includes clinical conditions with different grades of severity depending on onset of clinical complications, including gastrointestinal bleeding, hepatic encephalopathy (HE) and ascites.

Generally, when the complications linked to the portal hypertension appear, the liver damage from cirrhosis cannot be reversed. However, specific treatments can stop or delay further progression and reduce complications.

This Special Issue will be a collection of manuscripts providing an overview of the current research of treatment and prognosis in cirrhosis and complications.

The aim of this Special Issue is to provide a complete overview of the treatment and complications in the cirrhosis progression, finding any possible predictor of clinical outcome including specific treatment, lifestyle changes, involves molecular mechanisms, new drugs or surgery, and bacterial infections in cirrhosis. We welcome the submission of original papers and reviews regarding cirrhosis.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)